Security key
03836J201
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE)
CUSIP: 03836J201
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common stock, par value $0.001 per share
- Shares outstanding
- 9,144,889
- Total 13F shares
- 2,077,381
- Share change
- +64,141
- Total reported value
- $6,829,282
- Price per share
- $3.29
- Number of holders
- 26
- Value change
- +$211,103
- Number of buys
- 8
- Number of sells
- 4
Report period
Q4 2024
Institutions
26
Top holders
10
APRE full security history
Newer quarter: Q1 2025
Previous quarter: Q3 2024
Aprea Therapeutics, Inc. SEC filings
Aprea Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 03836J201
Recent filing periods:
Top shareholders of APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Sio Capital Management, LLC |
13F
13D/G
|
Company |
5.1%
from 13D/G
|
276,603
|
$760,658 | — | 30 Sep 2024 | |
| AIGH Capital Management LLC |
13F
|
Company |
5.9%
|
539,300
|
$1,483,075 | — | 30 Sep 2024 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
3%
|
270,000
|
$742,500 | — | 30 Sep 2024 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
2.2%
|
205,760
|
$565,840 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.9%
|
173,842
|
$478,066 | — | 30 Sep 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
1.5%
|
137,174
|
$377,229 | — | 30 Sep 2024 | |
| Exome Asset Management LLC |
13F
|
Company |
1.5%
|
137,174
|
$377,229 | — | 30 Sep 2024 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
1.5%
|
137,174
|
$377,229 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.44%
|
40,067
|
$110,201 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.37%
|
34,208
|
$94,072 | — | 30 Sep 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.19%
|
17,064
|
$46,926 | — | 30 Sep 2024 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.15%
|
13,864
|
$38,000 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0.09%
|
8,504
|
$23,386 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.05%
|
4,852
|
$13,344 | — | 30 Sep 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.02%
|
2,160
|
$5,940 | — | 30 Sep 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
1,315
|
$3,616 | — | 30 Sep 2024 | |
| MB, LEVIS & ASSOCIATES, LLC |
13F
|
Company |
0.01%
|
806
|
$2,217 | — | 30 Sep 2024 | |
| WealthCollab, LLC |
13F
|
Company |
0%
|
158
|
$435 | — | 30 Sep 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
150
|
$413 | — | 30 Sep 2024 | |
| NBC SECURITIES, INC. |
13F
|
Company |
0%
|
899
|
$2,000 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
11
|
$30 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
3
|
$8 | — | 30 Sep 2024 | |
| Christian S. Schade |
3/4/5
|
Director |
—
mixed-class rows
|
312,846
mixed-class rows
|
$976,345 | — | 28 Jul 2022 | |
| Scott M. Coiante |
3/4/5
|
SVP, Chief Financial Officer |
—
mixed-class rows
|
234,265
mixed-class rows
|
$533,970 | — | 28 Jul 2022 | |
| Eyal C. Attar |
3/4/5
|
SVP, Chief Medical Officer, Director |
—
class O/S missing
|
57,392
|
$211,254 | — | 03 Jun 2022 | |
| Gregory Alan Korbel |
3/4/5
|
SVP, Chief Operating Officer |
—
mixed-class rows
|
81,462
mixed-class rows
|
$168,445 | — | 28 Jul 2022 | |
| Lars B. Abrahmsen |
3/4/5
|
SVP, Chief Scientific Officer |
—
mixed-class rows
|
143,700
mixed-class rows
|
$160,855 | — | 10 Mar 2022 | |
| Nadeem Q. Mirza |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
33,650
mixed-class rows
|
$49,062 | — | 01 May 2024 | |
| Fouad Namouni |
3/4/5
|
Director |
—
mixed-class rows
|
27,360
mixed-class rows
|
$16,969 | — | 30 Jun 2021 | |
| Michael Aaron Kelly |
3/4/5
|
Director |
—
mixed-class rows
|
27,360
mixed-class rows
|
$16,969 | — | 30 Jun 2021 |
Institutional Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q4 2024
As of 31 Dec 2024,
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,077,381 shares.
The largest 10 holders included
AIGH Capital Management LLC, Sio Capital Management, LLC, SPHERA FUNDS MANAGEMENT LTD., Nantahala Capital Management, LLC, VANGUARD GROUP INC, Stonepine Capital Management, LLC, DAFNA Capital Management LLC, Exome Asset Management LLC, GEODE CAPITAL MANAGEMENT, LLC, and MORGAN STANLEY.
This page lists
26
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
21
Q4 2024 holders
26
Holder diff
5
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.